EU/03/14/1275

Table of contents

About

On 10 June 2014, orphan designation (EU/03/14/1275) was granted by the European Commission to Gene Signal SAS, France, for aganirsen for the treatment of central retinal vein occlusion.

Key facts

Active substance
Aganirsen
Disease / condition
Treatment of central retinal vein occlusion
Date of first decision
10/06/2014
Outcome
Positive
EU designation number
EU/03/14/1275

Sponsor's contact details

Gene Signal SAS
4, rue Pierre Fontaine
91000 Evry
France
Tel. +33 155 6012 55
Fax +33 155 6012 56
E-mail: marconi@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;
  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating